Cachexia News and Research

RSS

Cachexia is a condition which denotes the excessive loss of weight. It occurs because of the depletion of adipose tissue and muscle mass in people who are not trying to lose weight.

Study highlights impact of diet, exercise on prevention, treatment and survivorship of cancer

This Special Issue titled "The role of diet, body composition, and physical activity on cancer prevention, treatment, and survivorship" comprises both invited reviews and original papers investigating various themes such as the role of omega-3 fatty acids, amino acids, cancer cachexia, muscle health, exercise training, adiposity and body composition.

30 May 2014

IRB Barcelona scientists develop new drug target to prevent muscle deterioration in certain diseases

In the study published today in the Journal of Clinical Investigation (JCI), one of the journals with highest impact in experimental medicine, the researchers associate the activity of the DOR protein with muscle atrophy and point to DOR as a plausible target against which to develop a drug to prevent muscle deterioration in certain diseases.

10 Apr 2014

New antibody could boost strength, muscle mass in patients with cancer and other diseases

A new antibody could dramatically boost strength and muscle mass in patients with cancer, chronic obstructive pulmonary disease, sporadic inclusion body myositis, and in elderly patients with sarcopenia according to research published ahead of print in the journal Molecular and Cellular Biology.

20 Dec 2013

Chronic bronchitis could indicate COPD subtype

Chronic bronchitis is common among patients with chronic obstructive disease and may represent a subtype of the disease that places patients at risk for increased severity and exacerbations, say researchers.

22 Nov 2013

Helsinn grants exclusive commercialization rights to Chugai Pharma Marketing for anamorelin drug

Swiss-based Helsinn group has granted Chugai Pharma Marketing Ltd., a wholly-owned subsidiary of Chugai Pharmaceutical Co., Ltd., exclusive commercialization rights to their innovative ghrelin receptor agonist, anamorelin, for the three major European pharma markets.

12 Nov 2013

Study reveals that tumors factors inhibit repair of damaged muscle fibers during cancer wasting

A new study reveals that tumors release factors into the bloodstream that inhibit the repair of damaged muscle fibers, and that this contributes to muscle loss during cancer wasting.

24 Oct 2013

Study on the development of internet-based physical activity intervention presented at EULAR 2013

Results of the first study involving RA patients in the development of an internet-based physical activity intervention were presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism.

13 Jun 2013

Doctors should conduct frail screening to prevent bad outcomes

Everyone older than 70 should be checked for frailty, a condition that is both easily treated and potentially deadly, according to an article by representatives from six major international and U.S. medical organizations.

5 Jun 2013

XBiotech announces enrollment of first patient in Xilonix Phase III trial for treatment of cachexia

XBiotech announced today enrollment of the first patient into its Phase III trial of Xilonix. The Pivotal study is designed to improve health and survival of late stage colorectal cancer patients with associated cachexia.

25 Apr 2013

Phase II trial results of OHR/AVR118 in patients with cancer cachexia announced

Ohr Pharmaceutical, a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced the results of a Phase II trial to evaluate the effects of OHR/AVR118 in advanced cancer patients with cachexia. Cancer cachexia is the complex, multi-symptom syndrome seen in late-stage cancer patients, characterized by anorexia and unintended loss of appetite, progressive and continual weight loss, accompanied by generalized host tissue wasting, skeletal muscle atrophy, immune and metabolic dysfunction, and a greatly diminished quality of life.

21 Mar 2013

PsiOxus completes enrollment in MT-102 Phase II trial on cancer cachexia

PsiOxus Therapeutics, Ltd. (PsiOxus), a development stage biotechnology company, has completed patient enrollment for its Phase II clinical trial to study MT-102, a small molecule therapeutic for the treatment of cancer cachexia.

4 Mar 2013

Inflammation could hinder energy intake in advanced cancer

Energy intake, particularly energy density, is positively associated with energy balance in patients with advanced cancer, report Swedish researchers.

30 Jan 2013

DRCRF announces recipients of Nov. 2012 Damon Runyon Fellows

The Damon Runyon Cancer Research Foundation, a non-profit organization focused on supporting innovative early career researchers, named 15 new Damon Runyon Fellows at its fall Fellowship Award Committee review.

29 Jan 2013

TSC22D4 gene plays a key role in the onset of cachexia

Cachexia or wasting is a condition affecting up to 70 percent of cancer patients, depending on the type of cancer. It is characterized by a dramatic loss of body weight that is independent of food intake. Cachexia is seen particularly often and most pronounced in patients suffering from cancers of the digestive tract and the lungs.

16 Jan 2013

Myostatin responsible for initiation of muscle loss: Study

A research study from Nanyang Technological University (NTU) has yielded important breakthroughs on how the body loses muscle, paving the way for new treatments for aging, obesity and diabetes.

19 Dec 2012

Scientists isolate previously unknown protein in skeletal muscle

Scientists at Dana-Farber Cancer Institute have isolated a previously unknown protein in muscles that spurs their growth and increased power following resistance exercise. They suggest that artificially raising the protein's levels might someday help prevent muscle loss caused by cancer, prolonged inactivity in hospital patients, and aging.

7 Dec 2012

Positive interim data from XBiotech monoclonal antibody Phase II study for type 2 diabetes

XBiotech, a privately held biotechnology company, announced positive interim analysis results today from a Phase II study using a True Human monoclonal antibody (MABp1) in patients with type 2 diabetes. Results from this study continue to reinforce the role of IL-1α as a master regulator of chronic inflammation in multiple disease states, and the therapeutic benefits of neutralizing antibodies produced from the XBiotech platform.

29 Oct 2012

FDA grants Fast Track designation to XBiotech’s Xilonix for treatment of cachexia

XBiotech, a privately held biotechnology company, announced today that the company has been granted Fast Track designation for its anti-cachexia drug Xilonix.

4 Oct 2012

Karolinska Institutet professor receives Fernström Foundation Nordic Prize for obesity research

This year's Fernström Foundation Nordic Prize, worth SEK 1 million, goes to Professor Peter Arner from Karolinska Institutet, Sweden, who conducts research on fat. His team was the first to show that fat cells are formed throughout one's lifetime, not just in childhood.

11 Sep 2012

Aeterna Zentaris commences enrollment in AEZS-130 Phase 2A trial for cancer cachexia

Aeterna Zentaris Inc. today announced that a first patient has been recruited for a Phase 2A trial with its ghrelin agonist, AEZS-130 in patients with cancer cachexia.

28 Aug 2012